Latest clinical evidence on intravascular lithotripsy from EuroPCR 2025

In this #europcr 2025 roundtable, Niels Thue Olsen and Margaret McEntegart discuss with Flavio Luciano Ribichini the latest data on intravascular lithotripsy (IVL), based on two pivotal studies.

• EMPOWER CAD: the first prospective, real-world PCI trial dedicated to women with complex, calcified coronary artery disease. With an IVL-first strategy in 399 patients, the study demonstrated low rates of adverse events (~1.5%) and high procedural success.
• BALI Trial: a randomized study evaluating early IVL use versus conventional lesion preparation in severely calcified arteries. IVL showed superior outcomes on both procedural and clinical endpoints, even when rotational atherectomy was required.

A comprehensive overview of IVL’s role in the treatment of complex coronary disease!

This interview was filmed at EuroPCR 2025: see more videos here.